Targeting the histone orthography of cancer: Drugs for writers, erasers and readers

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2716-2732

  Simõ Riudalbas, Laia ^a   Esteller, Manel ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANACARDIC ACID; ANTINEOPLASTIC AGENT; BROMODOMAIN PROTEIN; C 646; CELL PROTEIN; CHAETOCIN; CURCUMIN; DOT1L HISTONE METHYLTRANSFERASE; EI 1; EPZ 004777; EPZ 005687; GSK 126; H3K9 METHYLTRANSFERASE; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; JMJC DOMAIN CONTAINING DEMETHYLASE; LSD HISTONE DEMETHYLASE; MITHRAMYCIN; MONOAMINE OXIDASE INHIBITOR; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; ORY 1001; PINOMETOSTAT; PROTEIN ARGININE METHYLTRANSFERASE; TAZEMETOSTAT; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG; HISTONE DEACETYLASE INHIBITOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CARCINOGENESIS; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; HISTONE METHYLATION; HUMAN; LOSS OF FUNCTION MUTATION; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84929166052     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12844     Document Type: Review

References (172)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol, 170: 1797-1867.
2. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R, (2013). Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12: 2113-2119.
3. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, et al. (2013). Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood 122: 2104-2113.
4. Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, et al. (2009). JNJ-26481585, a novel 'second-generation' oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 15: 6841-6851.
5. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, et al. (2004). Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279: 33716-33726.
6. Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, et al. (2012). A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res 18: 2687-2694.
7. Bannister AJ, Kouzarides T, (2011). Regulation of chromatin by histone modifications. Cell Res 21: 381-395.
8. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
9. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
10. Barth TK, Imhof A, (2010). Fast signals and slow marks: the dynamics of histone modifications. Trends Biochem Sci 35: 618-626.
11. Baylin SB, Jones PA, (2011). A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11: 726-734.
12. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A, (2009). An operational definition of epigenetics. Genes Dev 23: 781-783.
13. Bolden JE, Peart MJ, Johnstone RW, (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
14. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, et al. (2010). Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17: 471-482.
15. Bressi JC, Jennings AJ, Skene R, Wu Y, Melkus R, Jong RD, et al. (2010). Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl) benzamides. Bioorg Med Chem Lett 20: 3142-3145.
16. Cassier P, Floquet A, Penel N, Derbel O, N'guyen BB, Guastalla J-P, et al. (2014). The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors. Ann Oncol 25: 1074-1075.
17. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471: 513-517.
18. Chaib H, Nebbioso A, Prebet T, Castellano R, Garbit S, Restouin A, et al. (2012). Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia 26: 662-674.
19. Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, et al. (2014). Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123: 697-705.
20. Chan S-T, Yang N-C, Huang C-S, Liao J-W, Yeh S-L, (2013). Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS ONE 8: e54255.
21. Chang KH, King ON, Tumber A, Woon EC, Heightman TD, McDonough MA, et al. (2011). Inhibition of histone demethylases by 4-carboxy-2, 2′-bipyridyl compounds. ChemMedChem 6: 759-764.
22. Chang Y, Zhang X, Horton JR, Upadhyay AK, Spannhoff A, Liu J, et al. (2009). Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 16: 312-317.
23. Cherblanc FL, Chapman KL, Brown R, Fuchter MJ, (2013). Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol 9: 136-137.
24. Chesworth R, Wigle TJ, Kuntz KW, Smith JJ, Richon VM, (2014). Histone methyltransferases: opportunities in cancer drug discovery. In:, Lübbert M, Jones PA, (eds). Epigenetic Therapy of Cancer. Springer-Verlag: Berlin, Heidelberg, pp. 189-226.
25. Chi P, Allis CD, Wang GG, (2010). Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469.
26. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
27. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, et al. (2006). The putative oncogene GASC1 demethylates tri-and dimethylated lysine 9 on histone H3. Nature 442: 307-311.
28. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. (2012). Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30: 631-636.
29. Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, et al. (2011). A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 28: 540-546.
30. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. (2011). Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53-65.
31. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122: 1017-1025.
32. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan W-I, et al. (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Nature 478: 529-533.
33. De Boer J, Walf-Vorderwülbecke V, Williams O, (2013). In focus: MLL-rearranged leukemia. Leukemia 27: 1224-1228.
34. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
35. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, et al. (2013). Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121: 2533-2541.
36. Ehrbrecht A, Müller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, et al. (2006). Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208: 554-563.
37. Eliseeva ED, Valkov V, Jung M, Jung MO, (2007). Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 6: 2391-2398.
38. Esteller M, (2008). Epigenetics in cancer. NEJM 358: 1148-1159.
39. Filippakopoulos P, Knapp S, (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13: 337-356.
40. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. (2010). Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
41. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert J-P, Barsyte-Lovejoy D, et al. (2012). Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149: 214-231.
42. Fitzpatrick PF, (2010). Oxidation of amines by flavoproteins. Arch Biochem Biophys 493: 13-25.
43. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K, (2011). Peripheral T-cell lymphoma. Blood 117: 6756-6767.
44. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget M-C, Kalita A, et al. (2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759-768.
45. Fredly H, Gjertsen BT, Bruserud O, (2013). Histone deacetylase inhibition in the treatment of acute myeloid leukemia-the effects of valproic acid on leukemic cells and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 5: e12.
46. French CA, (2010). Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol 63: 492-496.
47. Furumai R, Matsuyama A, Kobashi N, Lee K-H, Nishiyama M, Nakajima H, et al. (2002). FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921.
48. Garcia-Manero G, Fenaux P, (2011). Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29: 516-523.
49. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
50. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE, (2006). Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66: 11298-11304.
51. Greenwald RJ, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, et al. (2004). Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 103: 1475-1484.
52. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A, (2005). Identification of a specific inhibitor of the histone methyltransferase SU (VAR) 3-9. Nat Chem Biol 1: 143-145.
53. Gyuris A, Donovan DJ, Seymour KA, Lovasco LA, Smilowitz NR, Halperin AL, et al. (2009). The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochim Biophys Acta 1789: 413-421.
54. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, et al. (2010). Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 9: e59.
55. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. (2011). Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128: 574-586.
56. He J, Nguyen AT, Zhang Y, (2011). KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117: 3869-3880.
57. Hemshekhar M, Sebastin Santhosh M, Kemparaju K, Girish KS, (2012). Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin Pharmacol Toxicol 110: 122-132.
58. Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C, et al. (2011). Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 54: 2504-2511.
59. Holmlund T, Lindberg M, Grander D, Wallberg A, (2013). GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia 27: 578-585.
60. Hu J, Colburn NH, (2005). Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding. Mol Cancer Res 3: 100-109.
61. Huang Y, Greene E, Stewart TM, Goodwin AC, Baylin SB, Woster PM, et al. (2007). Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. PNAS 104: 8023-8028.
62. Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B, et al. (2009). Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 15: 7217-7228.
63. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
64. Jacobson RH, Ladurner AG, King DS, Tjian R, (2000). Structure and function of a human TAFII250 double bromodomain module. Science 288: 1422-1425.
65. Jagannath S, Dimopoulos MA, Lonial S, (2010). Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 34: 1111-1118.
66. James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, et al. (2013). Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 9: 184-191.
67. Jang MK, Mochizuki K, Zhou M, Jeong H-S, Brady JN, Ozato K, (2005). The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 19: 523-534.
68. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. (2011). Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1: 598-607.
69. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. (2006). Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66: 11341-11347.
70. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, et al. (2011). Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 50: 931-944.
71. Ke G, Jia X, Hong Y, Wenhua L, (2012). CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukemia cells. Biochem J 443: 735-746.
72. Khan O, La Thangue NB, (2012). HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94.
73. King ON, Li XS, Sakurai M, Kawamura A, Rose NR, Ng SS, et al. (2010). Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE 5: e15535.
74. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. PNAS 100: 11606-11611.
75. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8: 890-896.
76. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. (2013). Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. PNAS 110: 7922-7927.
77. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, MacNevin CJ, et al. (2013). An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 8: 1324-1334.
78. Kooistra SM, Helin K, (2012). Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13: 297-311.
79. Kouzarides T, (2007). Chromatin modifications and their function. Cell 128: 693-705.
80. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu J-T, Nicchitta CV, et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607.
81. Kruidenier L, Chung C-W, Cheng Z, Liddle J, Che K, Joberty G, et al. (2012). A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488: 404-408.
82. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. (2007). Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25: 473-481.
83. Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P, (2014). A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PLoS ONE 9: e93208.
84. Lan F, Collins RE, De Cegli R, Alpatov R, Horton JR, Shi X, et al. (2007). Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 448: 718-722.
85. Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, et al. (2000). HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5: 589-595.
86. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R, (2006). Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 13: 563-567.
87. Lee MG, Villa R, Trojer P, Norman J, Yan K-P, Reinberg D, et al. (2007). Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318: 447-450.
88. Lin RJ, Sternsdorf T, Tini M, Evans RM, (2001). Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20: 7204-7215.
89. Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, Wasney GA, et al. (2010). Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2, 4-diamino-7-aminoalkoxy-quinazolines. J Med Chem 53: 5844-5857.
90. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, et al. (2009). Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28: 4491-4500.
91. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, et al. (2008). The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451: 846-850.
92. Lohse B, Kristensen JL, Kristensen LH, Agger K, Helin K, Gajhede M, et al. (2011). Inhibitors of histone demethylases. Bioorg Med Chem 19: 3625-3636.
93. Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S, et al. (1999). A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 274: 15633-15645.
94. Lu Z, Tian Y, Salwen HR, Chlenski A, Godley LA, Raj JU, et al. (2013). Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. Anticancer Drugs 24: 484-493.
95. Lucas D, Davis M, Parthun M, Mone A, Kitada S, Cunningham K, et al. (2004). The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18: 1207-1214.
96. Luo J, Su F, Chen D, Shiloh A, Gu W, (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
97. Malhotra A, Nair P, Dhawan DK, (2014). Study to evaluate molecular mechanics behind synergistic chemo-preventive effects of curcumin and resveratrol during lung carcinogenesis. PLoS ONE 9: e93820.
98. Malik S, Roeder RG, (2010). The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet 11: 761-772.
99. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R, (2007). FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252.
100. Mantelingu K, Reddy B, Swaminathan V, Kishore AH, Siddappa NB, Kumar G, et al. (2007). Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol 14: 645-657.
101. Marks P, (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356.
102. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112.
103. McDonough MA, Loenarz C, Chowdhury R, Clifton IJ, Schofield CJ, (2010). Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol 20: 659-672.
104. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. PNAS 108: 16669-16674.
105. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. (2009). DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579-1588.
106. Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, et al. (2010). Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl) methyl] amino} bicyclo [3.1. 0] hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem 53: 8663-8678.
107. Morey L, Helin K, (2010). Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 35: 323-332.
108. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181-185.
109. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. (2005). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77-84.
110. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, et al. (2010). Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42: 665-667.
111. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, et al. (2010). SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9: 642-652.
112. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. (2005). hDOT1L links histone methylation to leukemogenesis. Cell 121: 167-178.
113. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al. (2007). DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714-717.
114. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. (2011). Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43: 830-837.
115. Paul VJ, Yeddanapalli LM, (1956). On the olefinic nature of anacardic acid from Indian cashew nut shell liquid. J Am Chem Soc 78: 5675-5678.
116. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
117. Pena PV, Davrazou F, Shi X, Walter KL, Verkhusha VV, Gozani O, et al. (2006). Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 442: 100-103.
118. Pfaffeneder T, Spada F, Wagner M, Brandmayr C, Laube SK, Eisen D, et al. (2014). Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. Nat Chem Biol 10: 574-581.
119. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. (2009). Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417.
120. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117: 5827-5834.
121. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, et al. (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721-728.
122. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. PNAS 109: 21360-21365.
123. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, et al. (2006). Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642.
124. Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, et al. (2011). Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 78: 199-210.
125. Rodriguez-Paredes M, de Paz AM, Simõ-Riudalbas L, Sayols S, Moutinho C, Moran S, et al. (2013). Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 33: 2807-2813.
126. Ropero S, Esteller M, (2007). The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25.
127. Ruiz-Carrillo A, Wangh LJ, Allfrey VG, (1975). Processing of newly synthesized histone molecules. Science 190: 117-128.
128. Ruthenburg AJ, Li H, Patel DJ, Allis CD, (2007). Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 8: 983-994.
129. Ryan RJ, Bernstein BE, (2012). Genetic events that shape the cancer epigenome. Science 336: 1513-1514.
130. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, et al. (2006). ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. PNAS 103: 19176-19181.
131. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. (1999). A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. PNAS 96: 4592-4597.
132. Santer FR, Höschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, et al. (2011). Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10: 1644-1655.
133. Sauve AA, (2010). Sirtuin chemical mechanisms. Biochim Biophys Acta 1804: 1591-1603.
134. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, et al. (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18: 605-611.
135. Segal E, Widom J, (2009). What controls nucleosome positions Trends Genet 25: 335-343.
136. Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF, et al. (2014). Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 13: e66.
137. Shi X, Hong T, Walter KL, Ewalt M, Michishita E, Hung T, et al. (2006). ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442: 96-99.
138. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953.
139. Shih AH, Abdel-Wahab O, Patel JP, Levine RL, (2012). The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12: 599-612.
140. Simõ-Riudalbas L, Esteller M, (2013). Cancer genomics identifies disrupted epigenetic genes. Hum Genet 133: 713-725.
141. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, et al. (2008). Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 26: 1940-1947.
142. Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynaud FI, Rogers P, et al. (2005). Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 4: 1521-1532.
143. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. (2011). HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 71: 4412-4422.
144. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, et al. (2011). Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102: 1298-1305.
145. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063.
146. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ, (2007). How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 14: 1025-1040.
147. Trojer P, Li G, Sims IIIRJ, Vaquero A, Kalakonda N, Boccuni P, et al. (2007). L3MBTL1, a histone-methylation-dependent chromatin lock. Cell 129: 915-928.
148. Tsukada Y-I, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, et al. (2006). Histone demethylation by a family of JmjC domain-containing proteins. Nature 439: 811-816.
149. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
150. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. (2011). A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 7: 566-574.
151. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, et al. (2013). A Phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res 19: 4262-4272.
152. Vickers CJ, Olsen CA, Leman LJ, Ghadiri MR, (2012). Discovery of HDAC inhibitors that lack an active site Zn2+-binding functional group. ACS Med Chem Lett 3: 505-508.
153. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, et al. (2012). Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 26: 1517-1526.
154. Waddington CH, (1952). Selection of the genetic basis for an acquired character. Nature 169: 625-626.
155. Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, et al. (2010). Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10: 524.
156. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, et al. (2011). Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 71: 7238-7249.
157. Wells R, Leber B, Zhu N, Storring J, (2014). Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence. Curr Oncol 21: 44-50.
158. West AC, Johnstone RW, (2014). New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124: 30-39.
159. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, et al. (2006). Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125: 467-481.
160. Whittaker SJ, Demierre M-F, Kim EJ, Rook AH, Lerner A, Duvic M, et al. (2010). Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28: 4485-4491.
161. Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, et al. (2012). Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer 131: 2704-2709.
162. Wu H, Zhang Y, (2011). Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 25: 2436-2452.
163. Wu J, Xie N, Wu Z, Zhang Y, Zheng YG, (2009). Bisubstrate inhibitors of the MYST HATs Esa1 and Tip60. Bioorg Med Chem 17: 1381-1386.
164. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, et al. (2005). Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 19: 535-545.
165. Yang Z-Q, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, et al. (2000). Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 60: 4735-4739.
166. Yoshida M, Kijima M, Akita M, Beppu T, (1990). Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179.
167. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, et al. (2011). Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12: 1222-1228.
168. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong T-C, Prince HM, et al. (2012). Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30: 2197-2203.
169. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, et al. (2012). Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 3: e1288.
170. Yuan Y, Wang Q, Paulk J, Kubicek S, Kemp MM, Adams DJ, et al. (2012). A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol 7: 1152-1157.
171. Zee BM, Levin RS, Xu B, LeRoy G, Wingreen NS, Garcia BA, (2010). In vivo residue-specific histone methylation dynamics. J Biol Chem 285: 3341-3350.
172. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukemia. Nature 478: 524-528.